[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd. · NCT05641688
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 200
- US sites recruiting
- 17
- Study start
- December 1, 2022
- Record last updated
- October 23, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Being studied: [18F]PI-2620
Conditions: Alzheimer Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Only subjects who meet all of the following criteria will be eligible for enrollment into the study:
- Males and females aged 50 years and over
- Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
- Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
- Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure
Exclusion Criteria
Subjects will be excluded from the enrollment if they:
- Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
- Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically > 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
- Have suspected encephalopathy due to alcoholism or end-stage liver disease
- Are known to have a Glomerular Filtration Rate below \< 15 mL/min
- Have received an investigational or approved therapy directly targeting amyloid or tau
- Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
- Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)
Recruiting US locations
Barrow Neurological Institute
Phoenix, AZ 85013
Banner Sun Health Research Institute
Sun City, AZ 85352
UC Los Angeles
Los Angeles, CA 90095 - 7370
Esperanza Clinical
Murrieta, CA 92562
Sutter Health
San Francisco, CA 94114
Galiz Research
Hialeah, FL 33016
K2 Medical Research
Lady Lake, FL 32159
K2 Medical Research
Maitland, FL 32751
ClinCloud Research
Melbourne, FL 32940
Miami Jewish Health Systems
Miami, FL 33137
Charter Research
Winter Park, FL 32792
Alzheimer's Disease Center
Braintree, MA 02184
Ichor Research
Syracuse, NY 13219
Insight Clinical Trials LLC
Beachwood, OH 44131
Valley Medical Research
Centerville, OH 45459
Baylor Research Institute
Dallas, TX 75231
Sante Clinical Research
Kerrville, TX 78028
Study contacts (from the official record)
- Audrey Perrotin, PhD · +49 (0)30 461 1246 03 · clinicaltrials@lantheus.com
- Aleksandar Jovalekic, PhD · +49 (0)30 461 1246 03 · clinicaltrials@lantheus.com
Similar studies in Arizona
All neurology studies in Arizona →- RecruitingHealthy volunteersPhase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Suninflam Inc
- Location
- Tucson, AZ + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Sun City, AZ + 24 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Phoenix, AZ + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18–60